Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Annovis Bio, Inc. (ANVS : NYSE)
 
 • Company Description   
Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

Number of Employees: 3

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.15 Daily Weekly Monthly
20 Day Moving Average: 38,475 shares
Shares Outstanding: 8.16 (millions)
Market Capitalization: $74.70 (millions)
Beta: 2.11
52 Week High: $28.43
52 Week Low: $8.39
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -21.93% -14.52%
12 Week -36.68% -28.83%
Year To Date -47.95% -36.42%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1055 Westlakes Drive Suite 300
-
Berwyn,PA 19312
USA
ph: 610-727-3913
fax: -
nic.johnson@russopartnersllc.com http://www.annovisbio.com
 
 • General Corporate Information   
Officers
Maria Maccecchini - President and Chief Executive Officer
Michael Hoffman - Chairman of the Board and Director
Jeffrey McGroarty - Chief Financial Officer
Claudine Bruck - Director
Reid McCarthy - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03615A108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/27/22
Share - Related Items
Shares Outstanding: 8.16
Most Recent Split Date: (:1)
Beta: 2.11
Market Capitalization: $74.70 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.02 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/27/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.78
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -56.52%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -37.83
12/31/21 - -40.24
09/30/21 - -38.40
ROA
03/31/22 - -36.86
12/31/21 - -38.86
09/30/21 - -36.96
Current Ratio
03/31/22 - 34.47
12/31/21 - 30.52
09/30/21 - 42.51
Quick Ratio
03/31/22 - 34.47
12/31/21 - 30.52
09/30/21 - 42.51
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 5.15
12/31/21 - 5.49
09/30/21 - 5.74
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©